biOasis Enters Into a License Agreement With Medimmune for Second Generation Versions of biOasis's Transcend

biOasis Enters Into a License Agreement With Medimmune for Second Generation 
Versions of biOasis's Transcend 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: biOasis Technologies Inc. 
TSX VENTURE SYMBOL:  BTI
OTCQX SYMBOL:  BIOAF 
MARCH 17, 2014 
biOasis Enters Into a License Agreement With Medimmune for Second Generation
Versions of biOasis's Transcend 
This Represents A Positive Step Towards A New Therapeutic Approach For the
Treatment of CNS Diseases and Disorders 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 17, 2014) - BIOASIS
TECHNOLOGIES INC. (OTCQX:BIOAF)(TSX VENTURE:BTI), a pioneering
biopharmaceutical company focused on overcoming the limitations of therapeutic
drug delivery across the blood-brain barrier, has signed an evaluation
agreement with MedImmune, the global biologics research and development arm of
AstraZeneca.  
Under the terms of the agreement, MedImmune will evaluate the therapeutic
effect of its pre-clinical assets with next-generation versions of
biOasis's Transcend brain delivery platform. Efficient transport of drugs
targeted at the central nervous system is significantly hampered by the
blood-brain barrier; biOasis's Transcend platform, with its ability to
shuttle compounds across this barrier, may hold a solution to this problem.  
"Our working relationship with MedImmune began in November 2012. In our
collaboration, we demonstrated transport of MedImmune's antibodies into
the brain using our first-generation Transcend vector," said Dr. Reinhard
Gabathuler, Chief Scientist at biOasis. "In addition, we introduced our
second-generation Transcend vector into this collaboration and other programs
we have underway, where we have observed equivalent or increased antibody
transport into the brain. We feel that this next generation of Transcend will
have specific advantages in transporting certain biologics into the
brain."  
"MedImmune is pleased to be entering into this new agreement with
biOasis," said Dr. Carl Webster, Associate Director, Antibody Discovery
and Protein Engineering, MedImmune. "Our recently completed initial
collaboration was very positive and led us to decide to undertake this second
project to investigate the therapeutic effect and utility of biOasis's
technology."  
Financial terms were not disclosed. 
About biOasis 
biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the OTCQX under the symbol "BIOAF" and on the TSX
Venture Exchange under the symbol "BTI". For more information about
the company please visit www.bioasis.ca. 
Forward-Looking Statements 
Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may",
"plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar
expressions. Such forward-looking statements or information involve known and
unknown risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be materially
different from any future results, events or developments express or implied by
such forward-looking statements or information. Such factors include, among
others, our stage of development, lack of any product revenues, additional
capital requirements, risk associated with the completion of clinical trials
and obtaining regulatory approval to market our products, the ability to
protect our intellectual property, dependence on collaborative partners and the
prospects for negotiating additional corporate collaborations or licensing
arrangements and their timing. Specifically, certain risks and uncertainties
that could cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially from any future
events or results expressed or implied by such statements and information
include, but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials, or future
products in our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise additional
capital; we may not be successful in establishing additional corporate
collaborations or licensing arrangements; we may not be able to establish
marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein are based
on our current expectations and we undertake no obligation to revise or update
such forward- looking statements and information to reflect subsequent events
or circumstances, except as required by law. 
On Behalf of the Board of Directors 
Rob Hutchison Chairman & CEO  
"Neither the TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release." 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
778-383-3280
rob@bioasis.ca
or
Liolios Group, Inc. - Investor Relations Contact
Ron Both
Senior Managing Director
949-574-3860
BTI@liolios.com 
INDUSTRY:  Medical and Healthcare - Medical Devices, Pharmaceuticals and
Biotech - Biotech, Pharmaceuticals and Biotech - Equipment and Supplies 
SUBJECT:  BFC 
-0-
-0- Mar/17/2014 13:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.